PMID- 34604075 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211005 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases. PG - 737645 LID - 10.3389/fonc.2021.737645 [doi] LID - 737645 AB - Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric antigen receptor (CAR) T-cell therapy experience treatment failure and subsequently have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a potentially curative approach for patients in this situation. Induction of a deep response prior to alloHSCT is crucial for long-term outcomes, but the optimal bridging strategy following relapse after CAR T-cell therapy has not yet been established. Polatuzumab vedotin, an antibody drug conjugate targeting CD79b, is a novel treatment option for use in combination with rituximab and bendamustine (Pola-BR) in relapsed or refractory disease. Patients: We report two heavily pretreated patients with primary refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) respectively who relapsed after therapy with CAR T-cells with both nodal and extranodal manifestations of the disease. After application of three courses of Pola-BR both patients achieved a complete metabolic remission. Both patients underwent alloHSCT from a human leukocyte antigen (HLA)-mismatched donor following conditioning with busulfan and fludarabine and are disease free 362 days and 195 days after alloHSCT respectively. We conclude that Pola-BR can be an effective bridging therapy before alloHSCT of patients relapsing after CAR T-cell therapy. Further studies will be necessary to define the depth and durability of remission of this salvage regimen before alloHSCT. CI - Copyright (c) 2021 Gerhardt, Jentzsch, Georgi, Sretenovic, Cross, Bach, Monecke, Leiblein, Hoffmann, Todorovic, Bila, Sabri, Schwind, Franke, Platzbecker and Vucinic. FAU - Gerhardt, Kristin AU - Gerhardt K AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. FAU - Jentzsch, Madlen AU - Jentzsch M AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. FAU - Georgi, Thomas AU - Georgi T AD - Leipzig Medical Center, Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany. FAU - Sretenovic, Aleksandra AU - Sretenovic A AD - Clinical Center of Serbia, Institute for Hematology, University of Belgrade, Belgrade, Serbia. FAU - Cross, Michael AU - Cross M AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. FAU - Bach, Enrica AU - Bach E AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. FAU - Monecke, Astrid AU - Monecke A AD - Leipzig Medical Center, Institute for Histopathology, University of Leipzig, Leipzig, Germany. FAU - Leiblein, Sabine AU - Leiblein S AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. FAU - Hoffmann, Sandra AU - Hoffmann S AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. FAU - Todorovic, Milena AU - Todorovic M AD - Clinical Center of Serbia, Institute for Hematology, University of Belgrade, Belgrade, Serbia. FAU - Bila, Jelena AU - Bila J AD - Clinical Center of Serbia, Institute for Hematology, University of Belgrade, Belgrade, Serbia. FAU - Sabri, Osama AU - Sabri O AD - Leipzig Medical Center, Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany. FAU - Schwind, Sebastian AU - Schwind S AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. FAU - Franke, Georg-Nikolaus AU - Franke GN AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. FAU - Platzbecker, Uwe AU - Platzbecker U AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. FAU - Vucinic, Vladan AU - Vucinic V AD - Leipzig Medical Center, Clinic and Policlinic for Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany. LA - eng PT - Case Reports DEP - 20210916 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8481921 OTO - NOTNLM OT - CAR (chimeric antigen receptor) T cells OT - DLBCL OT - PMBCL OT - allogeneic hematopoeitic stem cell transplantation OT - polatuzumab vedotin COIS- G-NF, UP, and VV received Honoraria from Novartis and Gilead. MJ and SS received Honoraria from Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/05 06:00 MHDA- 2021/10/05 06:01 PMCR- 2021/01/01 CRDT- 2021/10/04 06:07 PHST- 2021/07/07 00:00 [received] PHST- 2021/08/25 00:00 [accepted] PHST- 2021/10/04 06:07 [entrez] PHST- 2021/10/05 06:00 [pubmed] PHST- 2021/10/05 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.737645 [doi] PST - epublish SO - Front Oncol. 2021 Sep 16;11:737645. doi: 10.3389/fonc.2021.737645. eCollection 2021.